: Merck’s COVID-19 pill could bring in up to $7 billion in sales next year

  • Written by MarketWatch
  • Published in Economics
Merck & Co. Inc. predicts it will make between $5 billion and $7 billion in sales of its experimental and potentially game-changing new oral COVID-19 drug by the end of 2022 if it's authorized this year.

Read more from our friends at MarketWatch